Skip to main content

Table 1 Effects of PUFA on cell-associated and secreted PrPSc

From: Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells

 

PrPSc (ng/ml)

Treatment

ScGT1 cells

ScN2A cells

SMB cells

 

Cell extracts

Supernatant

Cell extracts

Supernatant

Cell extracts

Supernatant

None

8.0 ± 1.0

1.42 ± 0.12

1.38 ± 0.14

0.45 ± 0.09

6.2 ± 1.1

3.1 ± 0.8

1 μM DHA

14.2 ± 1.7 *

4.64 ± 0.73 *

2.91 ± 0.71 *

1.12 ± 0.12 *

16.4 ± 3.7 *

5.7 ± 3.1 *

1 μM EPA

13.8 ± 2.4 *

3.42 ± 0.6 *

3.58 ± 0.52 *

0.96 ± 0.25 *

14.1 ± 2.2 *

4.8 ± 1.2 *

1 μM LA

8.4 ± 1.6

1.38 ± 0.21

1.43 ± 0.2

0.68 ± 0.4

7.7 ± 2.5

2.6 ± 0.75

1 μM LNA

7.8 ± 1.1

1.54 ± 0.46

1.63 ± 0.31

0.51 ± 0.22

7.1 ± 1.8

2.1 ± 1.15

1 μM AA

8.1 ± 1.5

1.56 ± 0.3

1.44 ± 0.3

0.59 ± 0.11

6.4 ± 1.5

2.5 ± 1.26

  1. The amounts of PrPSc in cell extracts (106 cells/ml) and in culture supernatants (equivalent to 106 cells/ml) from prion-infected neuronal cells treated for 7 days with 1 μM PUFA as shown. Amounts of PrPSc were measured by PrP-specific ELISA and are expressed as the mean average PrPSc (ng/ml) ± SD of ScGT1 (n = 15), ScN2a (n = 10) and SMB cells (n = 9). * = amounts of PrPC significantly different from that of untreated cells (P < 0.01).